SOPHiA GENETICS’s (SOPH) Buy Rating Reiterated at BTIG Research

BTIG Research reiterated their buy rating on shares of SOPHiA GENETICS (NASDAQ:SOPH) in a report published on Wednesday,Benzinga reports. BTIG Research currently has a $8.00 price target on the stock.

SOPH has been the topic of several other research reports. Guggenheim lifted their price target on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Tuesday, April 21st. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, SOPHiA GENETICS has an average rating of “Hold” and an average target price of $7.50.

SOPHiA GENETICS Stock Performance

Shares of SOPH stock opened at $5.15 on Wednesday. The company’s fifty day simple moving average is $4.84 and its 200-day simple moving average is $4.80. SOPHiA GENETICS has a 52 week low of $2.59 and a 52 week high of $5.70. The company has a current ratio of 2.06, a quick ratio of 1.84 and a debt-to-equity ratio of 1.05. The company has a market cap of $352.72 million, a PE ratio of -9.90 and a beta of 1.01.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. The business had revenue of $21.69 million during the quarter, compared to analysts’ expectations of $20.40 million.

Insider Activity at SOPHiA GENETICS

In other news, CEO Jurgi Camblong sold 43,129 shares of SOPHiA GENETICS stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $4.96, for a total value of $213,919.84. Following the completion of the transaction, the chief executive officer directly owned 3,664,440 shares of the company’s stock, valued at approximately $18,175,622.40. The trade was a 1.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 193,859 shares of company stock valued at $943,777. Insiders own 4.88% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Principal Financial Group Inc. boosted its holdings in shares of SOPHiA GENETICS by 0.7% in the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after buying an additional 9,800 shares during the period. Hodges Capital Management Inc. acquired a new position in SOPHiA GENETICS during the 1st quarter valued at about $2,157,000. First Dallas Securities Inc. acquired a new position in SOPHiA GENETICS during the 1st quarter valued at about $50,000. 1492 Capital Management LLC boosted its stake in SOPHiA GENETICS by 8.4% during the 1st quarter. 1492 Capital Management LLC now owns 225,751 shares of the company’s stock valued at $1,117,000 after purchasing an additional 17,406 shares during the period. Finally, Silverberg Bernstein Capital Management LLC boosted its stake in SOPHiA GENETICS by 8.7% during the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock valued at $257,000 after purchasing an additional 4,155 shares during the period. 31.59% of the stock is owned by institutional investors and hedge funds.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.